BE 
the Model

A philanthropic impact fund investing donations in for-profit companies bringing innovative, cancer-focused therapies and technologies to market.

Impact donors propel groundbreaking solutions being developed by innovative for-profit companies. Your tax-deductible contributions allow Bright Edge to invest with the goal of accelerating market delivery of today’s promising cancer-related solutions through capital investment, market awareness and a shared commitment to eradicate cancer. Impact donors will have visibility into today’s promising solutions and institutional-quality transparency into their measurable progress and impact.

Profile: Castle Biosciences
Leaders in cancer diagnostics, Castle Biosciences provides actionable, tumor-specific information to improve decision- making and patient care. Their DecisionDx-Melanoma molecular test has proven a significant, independent predictor of recurrence and metastatic risk. This technology saves lives by enabling better care management.

BE 
the Model

A philanthropic impact fund investing donations in for-profit companies bringing innovative, cancer-focused therapies and technologies to market.

Impact donors propel groundbreaking solutions being developed by innovative for-profit companies. Your tax-deductible contributions allow Bright Edge to invest with the goal of accelerating market delivery of today’s promising cancer-related solutions through capital investment, market awareness and a shared commitment to eradicate cancer. Impact donors will have visibility into today’s promising solutions and institutional-quality transparency into their measurable progress and impact.

Profile: Castle Biosciences
Leaders in cancer diagnostics, Castle Biosciences provides actionable, tumor-specific information to improve decision- making and patient care. Their DecisionDx-Melanoma molecular test has proven a significant, independent predictor of recurrence and metastatic risk. This technology saves lives by enabling better care management.

Profile: Castle Biosciences
Leaders in cancer diagnostics, Castle Biosciences provides actionable, tumor-specific information to improve decision- making and patient care. Their DecisionDx-Melanoma molecular test has proven a significant, independent predictor of recurrence and metastatic risk. This technology saves lives by enabling better care management.

A Charitable Fund

Investing for Impact
Donations to the American Cancer Society are dedicated to BrightEdge to invest in companies poised to have real impact on lives through four key strategies: prevention, therapeutics, diagnostics, and survivorship. By supporting market-ready solutions that help people today, we strive to reach a world without cancer sooner.
Adding Value
BrightEdge relies on the extensive scientific expertise of the American Cancer Society and other investment experts, toward making innovations commercially available to patients.
American Cancer Society Logo

$4.8

billion invested in research since 1946

47

Nobel Laureates funded before they were Nobel prize winners

27

percent decline in mortality rate

A Perpetual Fund Model

Reinvested Returns
100% of returns are reinvested into the American Cancer Society's life-saving work and mission, creating a perpetual fund model and compounding effect, so donor contributions have impact today that continues well into the future.

Exponential Impact

Institutional-quality reporting and “Impact Statements” from BrightEdge show donors the compounding impact of their dollars over time, and how they contribute to rapid progress toward the mission.